Inflammation is king in liver resection for hepatocellular carcinoma

We read with great interest the paper by Miyata et al. entitled: The Impact of Histologic Liver Inflammation on Oncology and the Prognosis of Patients Undergoing Hepatectomy for Hepatocellular Carcinoma (1). In this single center retrospective study, the authors included 500 patients undergoing curative surgical liver resection for primary hepatocellular carcinoma (HCC) without any neoadjuvant treatment. All liver specimen underwent postoperative pathological analysis to identify fibrosis but also lymphocyte infiltration and hepatocyte necrosis as surrogate marker for hepatic inflammation. Histological hepatic inflammation was graded from A0: no necro-inflammatory reaction, to A3: severe necro-inflammatory reaction. Median follow-up was 47.3 months. Overall, 19.4% of the patients had severe liver inflammation A3 (n=97) and presented with higher postoperative morbidity and reduced overall and recurrence-free survival compared to patients with none to moderate inflammation A0–A2 (n=403). Furthermore, inflammation grade A3 was an independent predictor of HCC recurrence independent of underlying liver disease and fibrosis grade.

The study by Miyata et al. contributes to the growing evidence on the importance of hepatic inflammation for tumor environment and oncological outcomes (2). HCC is particularly interesting since it develops under conditions of sustained inflammation (3). Data from animal studies show that upregulation of inflammatory cytokines after liver surgery triggers HCC recurrence (4,5). Interestingly, inflammation also impacts recurrence of HCC after liver transplantation (6). Results from a recent study suggest that treating liver grafts with ex-vivo machine perfusion prior to transplantation reduces recurrence rates by diminishing ischemia-reperfusion injury and inflammasome activation (7).

Based on the results of the study by Miyata et al., we would like to discuss two clinical factors that may impact hepatic inflammation and HCC recurrence in the setting of liver surgery. A first factor is the underlying liver disease. The type of inflammatory signaling differs for example in non-alcoholic fatty liver disease and virus induced hepatitis (8,9). This leads to a different immune surveillance of HCC which can be altered upon treatment and influence recurrence rates (10). For instance, HCV-related HCC has been shown to present high recurrence rates after adjuvant treatment with direct-acting antivirals (11). Of note, the majority of patients in the present study had HCV-related HCC but adjuvant treatments were not included in the analysis. Second, postoperative liver regeneration may also contribute to tumor recurrence (12). For example intraplatelet serotonin, a key player in hepatic regeneration, has been shown to impact early tumor recurrence after liver resection in humans (13). In the present paper only 27% of the patients underwent major hepatectomy and the authors do not specify if portal embolization was performed. An analysis of major hepatectomies with higher regeneration kinetics could further strengthen the authors hypothesis.

The study has several major limitations starting with the retrospective and single-center design. Another major limitation is the absence of potential confounding factors for recurrence in the analysis for example duration of pedicular clamping and adjuvant treatment. Also, there are no preoperative or peri-operative control biopsies available. Furthermore, the exact recurrence patterns are not investigated in the study. Finally, the pathological grading of inflammation is based on a classification dating back to 1996 (14). In contrast, a recent pilot study showed feasibility of real-time peri-operative determination of hepatic inflammation by video microscopy (15).

In conclusion, the results of the study support the idea of including hepatic inflammation as criterion for HCC risk-stratification with the potential to guide emerging adjuvant and neoadjuvant treatment strategies. Future studies should focus on major hepatectomies in patients with non-alcoholic fatty liver disease and perform an in-depth analysis of perioperative hepatic inflammation.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, Hepatobiliary Surgery and Nutrition. The article did not undergo external peer review.

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://hbsn.amegroups.org/article/view/10.21037/hbsn-21-435/coif). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.

References

1. Miyata T, Hayashi H, Yamashita YI, et al. The Impact of Histologic Liver Inflammation on Oncology and the Prognosis of Patients Undergoing Hepatectomy for Hepatocellular Carcinoma. Ann Surg Oncol 2021; Epub ahead of print. [Crossref] [PubMed]
2. Leone V, Ali A, Weber A, et al. Liver Inflammation and Hepatobiliary Cancers. Trends Cancer 2021;7:606-23. [Crossref] [PubMed]
3. Yu LX, Ling Y, Wang HY. Role of nonresolving inflammation in hepatocellular carcinoma development and progression. NPJ Precis Oncol 2018;2:6. [Crossref] [PubMed]
4. Wang D, Zheng X, Fu B, et al. Hepatectomy promotes recurrence of liver cancer by enhancing IL-11-STAT3 signaling. EBioMedicine 2019;46:119-32. [Crossref] [PubMed]
5. Orci LA, Lacotte S, Delaune V, et al. Effects of the gut-liver axis on ischaemia-mediated hepatocellular carcinoma recurrence in the mouse liver. J Hepatol 2018;68:978-85. [Crossref] [PubMed]
6. Schlegel A, Kron P, Graf R, et al. Hypothermic Oxygenated Perfusion (HOPE) downregulates the immune response in a rat model of liver transplantation. Ann Surg 2014;260:931-7; discussion 937-8. [Crossref] [PubMed]
7. Mueller M, Kalisvaart M, O'Rourke J, et al. Hypothermic Oxygenated Liver Perfusion (HOPE) Prevents Tumor Recurrence in Liver Transplantation From Donation After Circulatory Death. Ann Surg 2020;272:759-65. [Crossref] [PubMed]
8. Heymann F, Tacke F. Immunology in the liver--from homeostasis to disease. Nat Rev Gastroenterol Hepatol 2016;13:88-110. [Crossref] [PubMed]
9. Foerster F, Gairing SJ, Müller L, et al. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol. 2021:S0168-8278(21)02037-7. doi: 10.1016/j.jhep.2021.09.007.10.1016/j.jhep.2021.09.007
10. Heinrich B, Gertz EM, Schäffer AA, et al. The tumour microenvironment shapes innate lymphoid cells in patients with hepatocellular carcinoma. Gut 2021; [Epub ahead of print]. [Crossref] [PubMed]
11. Reig M, Mariño Z, Perelló C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol 2016;65:719-26. [Crossref] [PubMed]
12. Shi JH, Line PD. Effect of liver regeneration on malignant hepatic tumors. World J Gastroenterol 2014;20:16167-77. [Crossref] [PubMed]
13. Padickakudy R, Pereyra D, Offensperger F, et al. Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans. J Hepatol 2017;67:1243-52. [Crossref] [PubMed]
14. Ichida F, Tsuji T, Omata M, et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. International Hepatology Communications 1996;6:112. [Crossref]
15. Uz Z, Ince C, Shen L, et al. Real-time observation of microcirculatory leukocytes in patients undergoing major liver resection. Sci Rep 2021;11:4563. [Crossref] [PubMed]